Results
Transgene Biotek Reports FY26 Net Loss of ₹16.53 Crore
Transgene Biotek's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.
The company reported a significant net loss of ₹16.53 crore for FY26 and ₹4.